Tag: New Chemical Entity (NCE)

FDA Approves Evive Biotech’s Ryzneuta

FDA approves Evive Biotech’s Ryzneuta for the management of chemotherapy-induced neutropenia (incidence of infection, as

FDA approves BMS’ Repotrectinib (Augty

Bristol Myers Squibb Augtyro™ (repotrectinib) is approved for treatment of adult patients with ROS1-positive non-small

USFDA approves Santhera’s New Molecula

Vamorolone is a synthetic corticosteroid approved by USFDA for the treatment of Duchenne Muscular Dystrophy

FDA Approves Pfizer’s VELSIPITY  (etr

Velsipity (etrasimod) is an oral, once-daily, 2mg dose medication for adults with moderately to severely

FDA approves NCE Gepirone (EXXUA) for Ma

Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company announced approval of Exxua™ (gepirone hydrochloride extended-release tablets)

FDA Approves YCANTH For Treatment of Mol

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical

FDA on Friday approved Lexicon’s heart

</a> Marketing Authorisation on the request of MA holder Guidehouse Germany GmbH)

USFDA Grants First Full Approval for Pfi

USFDA has granted full approval for Pfizers Paxlovid, first Oral antiviral for COVID; This is

FDA Approves New Drug for Pneumonia

FDA has approved Xacduro injection (Durlobactam, a new molecular entity in combination with sulbactam) for